Seeking Alpha

An FDA panel has voted 3-14 that Abbott (ABT) has not found right dose for its irritable bowel...

An FDA panel has voted 3-14 that Abbott (ABT) has not found right dose for its irritable bowel syndrome drug Humira. Last week, FDA staff had questioned whether Humira had a real benefit for people with the disease who had already tried other treatments.
From other sites
Comments (2)
  • alexcampbello
    , contributor
    Comments (291) | Send Message
     
    share up 0.11 !!!!!!!!!!
    28 Aug 2012, 02:25 PM Reply Like
  • popster76
    , contributor
    Comments (338) | Send Message
     
    IBS or irritable bowel syndrome is a completely different condition from IBD or Inflammatory Bowel Disease. IBD consists of Crohn's Disease as well as Ulcerative Colitis, for which Humira was attempting to obtain another indication.
    28 Aug 2012, 03:06 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs